Detalhe da pesquisa
1.
GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma.
N Engl J Med
; 388(14): 1284-1295, 2023 Apr 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37018492
2.
Allogeneic, donor-derived, second-generation, CD19-directed CAR-T cells for the treatment of pediatric relapsed/refractory BCP-ALL.
Blood
; 142(2): 146-157, 2023 07 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-37172203
3.
FGFR1 is a potential therapeutic target in neuroblastoma.
Cancer Cell Int
; 22(1): 174, 2022 Apr 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-35488346
4.
Targeting cancer stem cells in medulloblastoma by inhibiting AMBRA1 dual function in autophagy and STAT3 signalling.
Acta Neuropathol
; 142(3): 537-564, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34302498
5.
CD28.OX40 co-stimulatory combination is associated with long in vivo persistence and high activity of CAR.CD30 T-cells.
Haematologica
; 106(4): 987-999, 2021 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32381575
6.
Establishment and Characterization of a Cell Line (S-RMS1) Derived from an Infantile Spindle Cell Rhabdomyosarcoma with SRF-NCOA2 Fusion Transcript.
Int J Mol Sci
; 22(11)2021 May 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-34067464
7.
GD2-targeting CAR T-cell therapy for patients with GD2+ medulloblastoma.
Clin Cancer Res
; 2024 Mar 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38551501
8.
High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells.
Blood
; 117(12): 3353-62, 2011 Mar 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-21278353
9.
The peculiar challenge of bringing CAR-T cells into the brain: Perspectives in the clinical application to the treatment of pediatric central nervous system tumors.
Front Immunol
; 14: 1142597, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37025994
10.
Spermine oxidase induces DNA damage and sensitizes fusion negative rhabdomyosarcoma cells to irradiation.
Front Cell Dev Biol
; 11: 1061570, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36755974
11.
Neutralizing IFNγ improves safety without compromising efficacy of CAR-T cell therapy in B-cell malignancies.
Nat Commun
; 14(1): 3423, 2023 06 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37296093
12.
MYOD-SKP2 axis boosts tumorigenesis in fusion negative rhabdomyosarcoma by preventing differentiation through p57Kip2 targeting.
Nat Commun
; 14(1): 8373, 2023 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38102140
13.
Overcoming Challenges in CAR T-cell Product CGMP Release.
Mol Ther
; 24(5): 845-6, 2016 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-27198849
14.
Nanoparticles for Diagnosis and Target Therapy in Pediatric Brain Cancers.
Diagnostics (Basel)
; 12(1)2022 Jan 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35054340
15.
PD-1-induced T cell exhaustion is controlled by a Drp1-dependent mechanism.
Mol Oncol
; 16(1): 188-205, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34535949
16.
Dual IGF1R/IR inhibitors in combination with GD2-CAR T-cells display a potent anti-tumor activity in diffuse midline glioma H3K27M-mutant.
Neuro Oncol
; 24(7): 1150-1163, 2022 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34964902
17.
MET Inhibition Sensitizes Rhabdomyosarcoma Cells to NOTCH Signaling Suppression.
Front Oncol
; 12: 835642, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35574376
18.
Time 2EVOLVE: predicting efficacy of engineered T-cells - how far is the bench from the bedside?
J Immunother Cancer
; 10(5)2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35577501
19.
Safe and effective off-the-shelf immunotherapy based on CAR.CD123-NK cells for the treatment of acute myeloid leukaemia.
J Hematol Oncol
; 15(1): 163, 2022 11 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36335396
20.
Time to evolve: predicting engineered T cell-associated toxicity with next-generation models.
J Immunother Cancer
; 10(5)2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35577500